NEW YORK (GenomeWeb) – Bio-Techne today announced a deal to buy protein analysis technology firm ProteinSimple for $300 million in cash.
ProteinSimple has appointed Joe Keegan and Chris van Ingen to its board of directors.
Keegan was previously the CEO of ForteBio and Molecular Devices.
Quanterix this week launched a commercial, research-use-only version of its Single Molecule Array, Simoa, platform.
ProteinSimple said this week that it has hired Terry Salyer as vice president of sales.
By Adam Bonislawski
A team led by Stanford University researchers has developed a method for predicting response to cancer therapies based on cellular signaling protein dynamics and changes in tumor size.
By a GenomeWeb staff reporter
Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.
The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.
Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.
In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.